SEM Semperit Holding AG

EQS-News: Semperit AG Holding Semperit successfully completes sale of medical business and focuses on growth in industrial core business

EQS-News: Semperit AG Holding / Key word(s): Disposal/Strategic Company Decision
Semperit AG Holding Semperit successfully completes sale of medical business and focuses on growth in industrial core business

31.08.2023 / 11:22 CET/CEST
The issuer is solely responsible for the content of this announcement.


Semperit successfully completes sale of medical business and focuses on growth in industrial core business

 

  • Transformation into industrial rubber/elastomer specialist implemented
  • Payment of additional dividend of EUR 3.00 per share on 14 September 2023

 

Vienna, 31 August 2023 – The Semperit Group has successfully completed the sale of its medical business to the Southeast Asian glove manufacturer HARPS GLOBAL PTE. LTD. After receiving all regulatory approvals, the closing took place as planned today, 31 August 2023, in Vienna. The purchase price for the entire medical business agreed upon signing the contract in December 2022 amounted to EUR 115 million (cash and debt free) and was subject to usual price adjustment mechanisms; the final purchase price will be determined in each case retrospectively based on the interim balance sheet as of the closing date.

“With the divestment of the medical business, we have implemented our transformation into an industrial rubber resp. elastomer specialist and will fully focus on the further development and expansion of our leading position in the core business for industrial polymer products in the future. This is where we see the greatest long-term potential for Semperit. An important growth step has already been taken with the acquisition of the Rico Group,” says Semperit CEO Karl Haider. “At the same time, we have found a responsible owner for the medical division in HARPS, which specialises in the glove business and thus expands its product portfolio and sales markets.”

With the closing, the Semperit Group has disposed of the production of examination gloves and porcelain dip mouldings for the manufacture of gloves in Malaysia, as well as the global sales and distribution units, in line with its strategy. This does not include the production of surgical gloves in Wimpassing, Austria, and their packaging in Sopron, Hungary, which will continue contract manufacturing for HARPS for several years.

Payment of additional dividend

With the sale of the medical business, all conditions precedent for the entitlement to and payment of the additional dividend in the amount of EUR 3.00 per share for the 2022 financial year have been fully met. The payment to shareholders will be made on 14 September 2023. As of 11 September 2023, the shares of Semperit AG Holding will be traded ex additional dividend. The record date is 12 September 2023.

 

 

Contact:

Bettina Schragl
Director Group Communications, IR and     Brand Management / Spokeswoman
57
@semperitgroup.com
Judit Helenyi
Director Investor Relations
 
10

 

About Semperit
The publicly listed Semperit AG Holding is an internationally oriented group of companies that develops and manufactures polymer products and sells them in over 100 countries worldwide with its two divisions, Industrial Applications and Engineered Applications. The Industrial Applications division focuses on industrial applications with highly efficient production and cost leadership; they include hydraulic and industrial hoses as well as profiles. The Engineered Applications division comprises escalator handrails, conveyor belts, cable car rings, other engineered elastomer products as well as the Rico Group and focuses on customised technical solutions. The traditional Austrian company was founded in 1824 and is headquartered in Vienna. At the end of 2022, the Group had 16 production sites worldwide and numerous sales offices in Europe, Asia, Australia and America. In the 2022 financial year, the Group generated sales of EUR 779.8 million and EBITDA of EUR 100.5 million in continued operations.

 

 



31.08.2023 CET/CEST This Corporate News was distributed by EQS Group AG.


Language: English
Company: Semperit AG Holding
Am Belvedere 10
1100 Wien
Austria
Phone: 0
Fax: 2
E-mail:
Internet:
ISIN: AT0000785555
Listed: Vienna Stock Exchange (Official Market)
EQS News ID: 1715995

 
End of News EQS News Service

1715995  31.08.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1715995&application_name=news&site_id=research_pool
EN
31/08/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Semperit Holding AG

 PRESS RELEASE

EQS-News: Semperit with stable revenue and 9% EBITDA increase in Q1 20...

EQS-News: Semperit AG Holding / Key word(s): Quarter Results Semperit with stable revenue and 9% EBITDA increase in Q1 2024 15.05.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Semperit with stable revenue and 9% EBITDA increase in Q1 2024   Continued operations with revenue of EUR 176.0 million (–0.2%) and EBITDA of EUR 23.0 million (+9.4%) Cost reductions initiated in the previous year already reduced expenses by EUR 9.9 million, of which EUR 4.1 million was attributable to Q1 2024 EBITDA guidance of around EUR 80 milli...

 PRESS RELEASE

EQS-News: Semperit im Q1 2024 mit stabilem Umsatz und 9% EBITDA-Plus

EQS-News: Semperit AG Holding / Schlagwort(e): Quartalsergebnis Semperit im Q1 2024 mit stabilem Umsatz und 9% EBITDA-Plus 15.05.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Semperit im Q1 2024 mit stabilem Umsatz und 9% EBITDA-Plus Fortgeführte Geschäftsbereiche mit Umsatz von 176,0 Mio. EUR (–0,2%) und EBITDA von 23,0 Mio. EUR (+9,4%) Im Vorjahr eingeleitete Kostensenkungen reduzierten Aufwand bereits um 9,9 Mio. EUR, davon entfielen 4,1 Mio. EUR auf Q1 2024 EBITDA-Guidance für das Gesamtjahr mit rund 80 Mio. EUR...

Semperit Holdings Ag: 1 director

A director at Semperit Holdings Ag bought 5,800 shares at 11.686EUR and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

 PRESS RELEASE

EQS-News: Semperit nach Transformationsjahr gestärkt für weiteres Wach...

EQS-News: Semperit AG Holding / Schlagwort(e): Jahresergebnis Semperit nach Transformationsjahr gestärkt für weiteres Wachstum – Ergebnis 2023 noch vom verkauften Medizingeschäft belastet 19.03.2024 / 07:34 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Semperit nach Transformationsjahr gestärkt für weiteres Wachstum – Ergebnis 2023 noch vom verkauften Medizingeschäft belastet   Fortgeführte Geschäftsbereiche mit Umsatz von 721,1 Mio. EUR (–7,5%), EBITDA von 71,8 Mio. EUR (–28,5%) und positivem Ergebnis nach Steuern von 24,9 Mio. E...

 PRESS RELEASE

EQS-News: Semperit strengthened for further growth after transformatio...

EQS-News: Semperit AG Holding / Key word(s): Annual Results Semperit strengthened for further growth after transformation year – earnings 2023 still burdened by sold medical business 19.03.2024 / 07:34 CET/CEST The issuer is solely responsible for the content of this announcement. Semperit strengthened for further growth after transformation year – earnings 2023 still burdened by sold medical business   Continued operations with revenue of EUR 721.1 million (–7.5%), EBITDA of EUR 71.8 million (–28.5%) and positive earnings after tax of EUR 24.9 million (–35.2%) Cost re...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch